Pyrrole-imidazole polyamide targeted to break fusion sites in TMPRSS2 and ERG gene fusion represses prostate tumor growth

Cancer Sci. 2014 Oct;105(10):1272-8. doi: 10.1111/cas.12493. Epub 2014 Sep 18.

Abstract

Aberrant overexpression of ERG induced by the TMPRSS2-ERG gene fusion is likely involved in the development of prostate cancer. Synthetic pyrrole-imidazole (PI) polyamides recognize and attach to the minor groove of DNA with high affinity and specificity. In the present study, we designed a PI polyamide targeting TMPRSS2-ERG translocation breakpoints and assessed its effect on human prostate cancer cells. Our study identified that this PI polyamide repressed the cell and tumor growth of androgen-sensitive LNCaP prostate cancer cells. Targeting of these breakpoint sequences by PI polyamides could be a novel approach for the treatment of prostate cancer.

Keywords: Androgen receptor; TMPRSS2-ERG; fusion gene; prostate cancer; pyrrole-imidazole polyamide.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Line, Tumor
  • Cell Movement / drug effects
  • Cell Proliferation / drug effects
  • Gene Fusion*
  • Humans
  • Imidazoles / pharmacology*
  • Male
  • Mice
  • Nylons / pharmacology*
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / genetics
  • Prostatic Neoplasms / pathology
  • Pyrroles / pharmacology*
  • Serine Endopeptidases / genetics*
  • Trans-Activators / genetics*
  • Transcriptional Regulator ERG

Substances

  • ERG protein, human
  • Imidazoles
  • Nylons
  • Pyrroles
  • Trans-Activators
  • Transcriptional Regulator ERG
  • Serine Endopeptidases
  • TMPRSS2 protein, human